Colin Bristow
Stock Analyst at UBS
(1.63)
# 3,309
Out of 5,182 analysts
105
Total ratings
40.32%
Success rate
-5.29%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Therapeutics | Maintains: Neutral | $4 → $10 | $6.96 | +43.68% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $430.14 | +26.94% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $129.26 | -13.35% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $70.26 | +13.86% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.43 | +45.77% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.64 | -39.02% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $26.99 | -37.01% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $339.57 | -6.06% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $2.46 | +62.60% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $26.48 | +5.74% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $110.03 | +9.06% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $183.38 | +10.15% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.06 | +1,409.43% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $731.77 | +50.18% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $21.07 | +692.60% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $874.00 | -51.95% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $14.67 | -86.37% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.83 | +883.61% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $197.69 | -26.15% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $58.26 | +28.73% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.75 | +845.45% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $6.20 | +45.16% | 1 | Aug 23, 2021 |
enGene Therapeutics
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $6.96
Upside: +43.68%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $430.14
Upside: +26.94%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $129.26
Upside: -13.35%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $70.26
Upside: +13.86%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.43
Upside: +45.77%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.64
Upside: -39.02%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $26.99
Upside: -37.01%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $339.57
Upside: -6.06%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $2.46
Upside: +62.60%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.48
Upside: +5.74%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $110.03
Upside: +9.06%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $183.38
Upside: +10.15%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.06
Upside: +1,409.43%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $731.77
Upside: +50.18%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $21.07
Upside: +692.60%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $874.00
Upside: -51.95%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $14.67
Upside: -86.37%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.83
Upside: +883.61%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $197.69
Upside: -26.15%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $58.26
Upside: +28.73%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.75
Upside: +845.45%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $6.20
Upside: +45.16%